Cardinal Health, Inc. $CAH Stock: Krilogy Financial LLC Raises Holdings

Krilogy Financial LLC boosted its stake in Cardinal Health, Inc. (NYSE:CAH) by 151.4% during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 5,795 shares of the company’s stock after buying an additional 3,490 shares during the quarter. Krilogy Financial LLC’s holdings in Cardinal Health were worth $1,289,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of CAH. Downshift Financial LLC increased its position in Cardinal Health by 3,666.7% during the third quarter. Downshift Financial LLC now owns 113 shares of the company’s stock worth $25,000 after buying an additional 110 shares in the last quarter. Investors Research Corp acquired a new position in shares of Cardinal Health in the second quarter worth $29,000. Allied Private Wealth LLC purchased a new stake in shares of Cardinal Health in the second quarter valued at $30,000. NBH Bank purchased a new stake in shares of Cardinal Health in the second quarter valued at $31,000. Finally, Indiana Trust & Investment Management Co purchased a new stake in shares of Cardinal Health in the first quarter valued at $29,000. Hedge funds and other institutional investors own 87.17% of the company’s stock.

Cardinal Health Price Performance

Cardinal Health stock opened at $253.44 on Friday. The stock’s 50-day moving average is $234.20 and its 200-day moving average is $222.00. The company has a market cap of $58.69 billion, a price-to-earnings ratio of 35.05, a price-to-earnings-growth ratio of 1.49 and a beta of 0.50. Cardinal Health, Inc. has a 12 month low of $152.46 and a 12 month high of $258.30.

Cardinal Health (NYSE:CAH) last released its quarterly earnings data on Tuesday, August 11th. The company reported $2.91 earnings per share for the quarter, beating the consensus estimate of $2.42 by $0.49. The business had revenue of $63.67 billion for the quarter, compared to analyst estimates of $65.15 billion. Cardinal Health had a negative return on equity of 98.53% and a net margin of 0.67%. The company’s revenue was up 5.8% compared to the same quarter last year. During the same period in the previous year, the company posted $2.08 EPS. Cardinal Health has set its FY 2027 guidance at 12.400-12.600 EPS. Research analysts anticipate that Cardinal Health, Inc. will post 12.55 EPS for the current year.

Cardinal Health Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, October 15th. Shareholders of record on Thursday, October 1st were given a dividend of $0.5158 per share. This represents a $2.06 dividend on an annualized basis and a yield of 0.8%. The ex-dividend date of this dividend was Thursday, October 1st. Cardinal Health’s payout ratio is 28.49%.

Insider Activity

In other news, CEO Stephen M. Mason sold 35,000 shares of the stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $236.40, for a total value of $8,274,000.00. Following the completion of the sale, the chief executive officer owned 18,061 shares of the company’s stock, valued at $4,269,620.40. This represents a 65.96% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Michelle D. Greene sold 11,650 shares of the firm’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $235.72, for a total transaction of $2,746,138.00. Following the completion of the transaction, the insider directly owned 10,330 shares in the company, valued at approximately $2,434,987.60. This represents a 53.00% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 210,271 shares of company stock valued at $49,626,657 over the last quarter. 0.12% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of analysts recently commented on the company. JPMorgan Chase & Co. lifted their price objective on Cardinal Health from $215.00 to $260.00 and gave the stock a “neutral” rating in a research report on Thursday, August 13th. Wells Fargo & Company upped their target price on shares of Cardinal Health from $245.00 to $277.00 and gave the company an “overweight” rating in a report on Wednesday, August 12th. Robert W. Baird upped their target price on shares of Cardinal Health from $251.00 to $274.00 and gave the company an “outperform” rating in a report on Wednesday, August 12th. TD Cowen raised their price target on shares of Cardinal Health from $275.00 to $280.00 and gave the stock a “buy” rating in a research note on Thursday, August 13th. Finally, Weiss Ratings upgraded shares of Cardinal Health from a “buy (b)” rating to a “buy (b+)” rating in a report on Thursday, October 8th. Sixteen equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $266.56.

Cardinal Health Company Profile

Cardinal Health, Inc is a healthcare services and products company that supports pharmacies, hospitals, ambulatory surgery centers, physician offices and other healthcare providers. Its operations are primarily organized into Pharmaceutical and Medical segments.

The Pharmaceutical segment distributes branded, generic, specialty and over-the-counter medicines, as well as consumer health products. It also provides services related to specialty pharmaceuticals, pharmaceutical sourcing, nuclear and precision health products, and data and analytics for pharmaceutical manufacturers and healthcare organizations.

The Medical segment distributes medical and surgical products, including gloves, apparel, incontinence supplies, laboratory products and other essential items.